产品
编 号：F747733
分子式：C14H22BO4P
分子量：296.11
分子式：C14H22BO4P
分子量：296.11
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 188714-28-5
产品详情
生物活性：
PB1 is a potent intracellular disulfide reducing agent with several advantages including good cell permeability, the ability to form a high intracellular concentration gradient, and stability. PB1 is a borane-protected TCEP (tris(2-carboxyethyl)phosphine) analogue. PB1 increases retinal ganglion cells survival after axotomy in vitro at nanomolar and picomolar concentrations. PB1 can be used for the research of neuroprotective.
体内研究：
PB1 (150 μM; intraocular injection; 1 week) attenuates the loss of both RGC (retinal ganglion cells) soma and axons in experimental glaucoma.PB1 protects RGC soma in experimental glaucoma. PB1 single dose limits the biological activity in vivo. PB1 attenuates the loss of both RGC soma and axons in experimental glaucoma. PB1 (0.001~100 μM; 72 hours) is effective at rescuing acutely axotomized retinal ganglion cells.Animal Model:Sprague-Dawley rats (180~200 g)
Dosage:150 μM
Administration:Intraocular injection
Result:PB1-treated eyes, 66% of RGCs survived at 1 week after axotomy.
体外研究：
PB1 produces a robust activation of the BDNF effector ERK1/2. PB1 promotes RGC survival.
PB1 is a potent intracellular disulfide reducing agent with several advantages including good cell permeability, the ability to form a high intracellular concentration gradient, and stability. PB1 is a borane-protected TCEP (tris(2-carboxyethyl)phosphine) analogue. PB1 increases retinal ganglion cells survival after axotomy in vitro at nanomolar and picomolar concentrations. PB1 can be used for the research of neuroprotective.
体内研究：
PB1 (150 μM; intraocular injection; 1 week) attenuates the loss of both RGC (retinal ganglion cells) soma and axons in experimental glaucoma.PB1 protects RGC soma in experimental glaucoma. PB1 single dose limits the biological activity in vivo. PB1 attenuates the loss of both RGC soma and axons in experimental glaucoma. PB1 (0.001~100 μM; 72 hours) is effective at rescuing acutely axotomized retinal ganglion cells.Animal Model:Sprague-Dawley rats (180~200 g)
Dosage:150 μM
Administration:Intraocular injection
Result:PB1-treated eyes, 66% of RGCs survived at 1 week after axotomy.
体外研究：
PB1 produces a robust activation of the BDNF effector ERK1/2. PB1 promotes RGC survival.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备